AR105335A1 - Anticuerpos monoclonales anti-sortilina - Google Patents

Anticuerpos monoclonales anti-sortilina

Info

Publication number
AR105335A1
AR105335A1 ARP160102109A ARP160102109A AR105335A1 AR 105335 A1 AR105335 A1 AR 105335A1 AR P160102109 A ARP160102109 A AR P160102109A AR P160102109 A ARP160102109 A AR P160102109A AR 105335 A1 AR105335 A1 AR 105335A1
Authority
AR
Argentina
Prior art keywords
sortiline
monoclonal antibodies
antibodies
programnulin
pgrn
Prior art date
Application number
ARP160102109A
Other languages
English (en)
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of AR105335A1 publication Critical patent/AR105335A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente se refiere a anticuerpos monoclonales anti-sortilina que se ha encontrado que son útiles en la corrección de un nivel deficiente de progranulina (PGRN). En particular, pueden usarse estos anticuerpos en el tratamiento de demencia frontotemporal (DFT) y esclerosis lateral amiotrófica (ELA).
ARP160102109A 2015-07-13 2016-07-12 Anticuerpos monoclonales anti-sortilina AR105335A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Publications (1)

Publication Number Publication Date
AR105335A1 true AR105335A1 (es) 2017-09-27

Family

ID=54013862

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102109A AR105335A1 (es) 2015-07-13 2016-07-12 Anticuerpos monoclonales anti-sortilina

Country Status (31)

Country Link
US (5) US10479835B2 (es)
EP (1) EP3322726A1 (es)
JP (2) JP6979397B2 (es)
KR (1) KR20180030045A (es)
CN (3) CN114478775A (es)
AR (1) AR105335A1 (es)
AU (1) AU2016292980B2 (es)
BR (1) BR112018000771A2 (es)
CA (1) CA2989739A1 (es)
CL (2) CL2018000092A1 (es)
CO (1) CO2017012988A2 (es)
CR (1) CR20180002A (es)
DO (1) DOP2018000014A (es)
EA (1) EA201890038A1 (es)
EC (1) ECSP18002725A (es)
GB (1) GB201512215D0 (es)
HK (1) HK1254356A1 (es)
IL (1) IL256503B (es)
JO (1) JO3710B1 (es)
MA (1) MA42440A (es)
MX (1) MX2018000506A (es)
NI (1) NI201800007A (es)
PE (1) PE20181014A1 (es)
PH (1) PH12018500100A1 (es)
RU (1) RU2735639C2 (es)
SV (1) SV2018005613A (es)
TN (1) TN2017000534A1 (es)
TW (1) TWI760305B (es)
UA (1) UA125136C2 (es)
WO (1) WO2017009327A1 (es)
ZA (1) ZA201708613B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201792221A1 (ru) * 2015-04-07 2018-08-31 ЭЛЕКТОР ЭлЭлСи Антитела против сортилина и способы их применения
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
HRP20230344T1 (hr) * 2018-07-13 2023-06-09 Alector Llc Protutijela protiv sortilina i postupci njihove upotrebe
WO2023247754A1 (en) 2022-06-23 2023-12-28 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2125854T3 (es) 1989-08-09 1999-03-16 Rhomed Inc Radiomarcado directo de anticuerpos y otras proteinas con tecnetio o renio.
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
IL144084A0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP2003516718A (ja) 1999-07-29 2003-05-20 メダレックス インク ＨＥＲ２／ｎｅｕに対するヒトモノクローナル抗体
EP2829609A1 (en) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
WO2004056385A2 (en) 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
US8748384B2 (en) 2006-12-21 2014-06-10 H. Lundbeck A/S Modulation of activity of proneurotrophins
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
CN102131826B (zh) 2008-04-27 2014-07-02 H.隆德贝克有限公司 人类分拣蛋白的晶体结构及其用于鉴定分拣蛋白的配体的用途
JP2011524741A (ja) 2008-05-27 2011-09-08 協和発酵キリン株式会社 インターロイキン１０受容体（ｉｌ−１０ｒ）抗体及び使用方法
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
CN105641694B (zh) * 2008-12-19 2020-08-14 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
US9822366B2 (en) 2012-11-02 2017-11-21 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
EA201792221A1 (ru) 2015-04-07 2018-08-31 ЭЛЕКТОР ЭлЭлСи Антитела против сортилина и способы их применения
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
HRP20230344T1 (hr) 2018-07-13 2023-06-09 Alector Llc Protutijela protiv sortilina i postupci njihove upotrebe

Also Published As

Publication number Publication date
CN107849135A (zh) 2018-03-27
GB201512215D0 (en) 2015-08-19
KR20180030045A (ko) 2018-03-21
CA2989739A1 (en) 2017-01-19
RU2018100824A3 (es) 2020-01-17
SV2018005613A (es) 2018-02-23
US10889650B2 (en) 2021-01-12
BR112018000771A2 (pt) 2018-09-25
AU2016292980B2 (en) 2022-10-06
UA125136C2 (uk) 2022-01-19
US20170267761A1 (en) 2017-09-21
TN2017000534A1 (en) 2019-04-12
RU2735639C2 (ru) 2020-11-05
JP6979397B2 (ja) 2021-12-15
CL2020002468A1 (es) 2021-01-29
RU2018100824A (ru) 2019-08-13
US10479835B2 (en) 2019-11-19
CR20180002A (es) 2018-04-09
EP3322726A1 (en) 2018-05-23
US20230159643A1 (en) 2023-05-25
CO2017012988A2 (es) 2018-05-21
IL256503A (en) 2018-02-28
PE20181014A1 (es) 2018-06-26
WO2017009327A1 (en) 2017-01-19
US20180305455A1 (en) 2018-10-25
TW201702273A (zh) 2017-01-16
JP2018529635A (ja) 2018-10-11
ZA201708613B (en) 2021-03-31
US10428147B2 (en) 2019-10-01
US20200190188A1 (en) 2020-06-18
CL2018000092A1 (es) 2018-07-06
HK1254356A1 (zh) 2019-07-19
US11548950B2 (en) 2023-01-10
PH12018500100A1 (en) 2018-07-30
EA201890038A1 (ru) 2018-06-29
MX2018000506A (es) 2018-05-11
DOP2018000014A (es) 2018-04-15
ECSP18002725A (es) 2018-03-31
TWI760305B (zh) 2022-04-11
CN114478774A (zh) 2022-05-13
JO3710B1 (ar) 2021-01-31
MA42440A (fr) 2018-05-23
IL256503B (en) 2022-02-01
NI201800007A (es) 2018-10-18
US20210269524A1 (en) 2021-09-02
JP2022003058A (ja) 2022-01-11
AU2016292980A1 (en) 2018-01-18
CN114478775A (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2022005177A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
AR105335A1 (es) Anticuerpos monoclonales anti-sortilina
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112018008901A8 (pt) formulações subcutâneas de anticorpos anti-cd 38 e seus usos
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
EA202091989A1 (ru) Способы лечения язвенного колита
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
IN2014MU01248A (es)
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MA39355B2 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
EA201991471A1 (ru) Способы введения гепсидина